Key facts

Active Substance
Recombinant humanized anti-blood dendritic cell antigen 2 (BDCA2) monoclonal antibody (BIIB059)
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0055/2022
PIP number
EMEA-002555-PIP02-21
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of lupus erythematosus
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Biogen Netherlands B.V.

E-mail: pip.enquiries@biogen.com
Tel: +44 (0)1628512586

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page